

MIP-1α/CCL3

Catalog # PVGS1649

Product Information

Primary Accession P10147
Species Human

Sequence Ser24-Ala92

Purity > 95% as analyzed by SDS-PAGE

Endotoxin Level

Expression System E. coli

Formulation Lyophilized from a 0.2 Im filtered solution in 20 mM PB, 150 mM NaCl, pH

7.4.

Reconstitution It is recommended that this vial be briefly centrifuged prior to opening to

bring the contents to the bottom. Reconstitute the lyophilized powder in

distilled water up to 100 g/ml.

Storage & Stability Upon receiving, this product remains stable for up to 6 months at -70°C or

-20°C. Upon reconstitution, the product should be stable for up to 1 week at 4-7°C and up to 3 months at -20 °C or below. Avoid repeated freeze-thaw

cycles.

Additional Information

Gene ID 6348

Other Names C-C motif chemokine 3, G0/G1 switch regulatory protein 19-1, Macrophage

inflammatory protein 1-alpha, MIP-1-alpha, PAT 464.1, SIS-beta, Small-inducible cytokine A3, Tonsillar lymphocyte LD78 alpha protein, MIP-1-alpha(4-69), LD78-alpha(4-69), CCL3, G0S19-1, MIP1A, SCYA3

Target Background Human Chemokine (C-C Motif) Ligand 3 (CCL3) is a small cytokine belonging to

the CC chemokine family. CCL3 is primarily expressed in T cells, B cells, and

monocytes after antigen or mitogen stimulation. CCL3 exhibits

chemoattractive and adhesive effects on lymphocytes. CCL3 exerts multiple effects on hematopoietic precursor cells and inhibits the proliferation of hematopoietic stem cells in vitro as well as in vivo. CCR1 and CCR5 have been

identified as functional receptors for CCL3.

Protein Information

Name CCL3

Synonyms G0S19-1, MIP1A, SCYA3

Function Monokine with inflammatory and chemokinetic properties. Binds to CCR1,

CCR4 and CCR5. One of the major HIV-suppressive factors produced by CD8+T-cells. Recombinant MIP-1-alpha induces a dose- dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV).

Cellular Location Secreted.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.